Interstitial lung diseases (ILDs) comprise over 200 parenchymal lung disorders. Among
them, fibrosing ILDs, especially idiopathic pulmonary fibrosis, are associated with a poor …

Purpose The lack of effective molecular biomarkers to monitor idiopathic pulmonary fibrosis
(IPF) activity or treatment response remains an unmet clinical need. Herein, we determined …

Rationale: Sustained activation of lung fibroblasts and the resulting oversynthesis of the
extracellular matrix are detrimental events for patients with interstitial lung diseases (ILDs) …

Purpose Patients with idiopathic pulmonary fibrosis (IPF) show increased PET signal at sites
of morphological abnormality on high-resolution computed tomography (HRCT). The …

Purpose There is a lack of prognostic biomarkers in idiopathic pulmonary fibrosis (IPF)
patients. The objective of this study is to investigate the potential of 18 F-FDG-PET/CT to …

Interstitial lung diseases (ILDs) are a heterogeneous group of conditions, with a wide and
complex variety of imaging features. Difficulty in monitoring, treating and exploring novel …

Background The radiotracer fluorine 18 (18F)–labeled fibroblast activation protein inhibitor
(FAPI) has shown promise for visualizing several types of cancer, but the accuracy of 18F …

The purpose of this study was to evaluate integrated 18F-FDG PET/CT in patients with
idiopathic pulmonary fibrosis (IPF) and diffuse parenchymal lung disease (DPLD). Methods …

Pulmonary fibrosis is scarring of the lungs that can arise from radiation injury, drug toxicity,
environmental or genetic causes, and for unknown reasons [idiopathic pulmonary fibrosis …

Background Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by an
unpredictable course. Prognostic markers and disease activity markers are needed. The …